Scarica l'app Stockscreener
11.20
6.31%
0.665
Dopo l'orario di chiusura:
10.61
-0.59
-5.27%
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
PHATPhathom Pharmaceuticals Inc Revenue Breakdown - Finviz
Phathom Pharmaceuticals advances pivotal EoE acid suppression study to next stage - Traders Union
Discipline and Rules-Based Execution in PHAT Response - Stock Traders Daily
Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT) - TradingView
PHAT Forecast — Price Target — Prediction for 2027 - TradingView
Phathom Pharmaceuticals supports upcoming GI meetings as industry engagement expands - Traders Union
Phathom Pharmaceuticals details new Voquezna launch pace, shares track gastro health focus - AD HOC NEWS
Phathom Pharmaceuticals Inc (PHAT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - Moomoo
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phathom Pharmaceuticals (PHAT) Completes Enrollment in Clinical Trial - GuruFocus
Phathom completes enrollment in vonoprazan trial for EoE By Investing.com - Investing.com Australia
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study - Investing.com UK
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com - Investing.com Nigeria
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial - TipRanks
Phathom Pharmaceuticals Completes Enrollment in Phase 2 VOQUEZNA Clinical Trial for Eosinophilic Esophagitis, Results Expected Q4 2026 5 – Minichart - Minichart
Phathom completes enrollment in vonoprazan trial for EoE - Investing.com
Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026 - Stock Titan
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven? - 富途牛牛
Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PHAT Stock Price, Quote & Chart - ChartMill
Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Buy on Phathom stock, $26 target By Investing.com - Investing.com Canada
Behavioral Patterns of PHAT and Institutional Flows - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Surges 4.74% as Bullish Momentum BuildsBreakout Trade - newsline.com
Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Phathom Pharmaceuticals scheduled for 2:40 PM fireside chat at major healthcare event - Traders Union
Phathom: Why I’m Downgrading To "Sell" Ahead Of Competition (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference - Traders Union
(PHAT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Phathom Pharmaceuticals honors Tachi Yamada legacy in GI medicine - Traders Union
Phathom Pharmaceuticals (PHAT) Surges 4.44% as Stock Tests Key ResistanceWave Alternation - newsline.com
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs. - Pluang
[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Phathom Pharmaceuticals to engage investors at multiple conferences in May and June - Traders Union
How (PHAT) Movements Inform Risk Allocation Models - Stock Traders Daily
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Phathom Pharmaceuticals (PHAT) Slips 2.16% as Stock Tests Key Support LevelsOBV Divergence - thelegaladvocate.com
Hear Phathom at three upcoming healthcare investor conferences - Stock Titan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Director Mark Stenhouse awarded 24,122 RSUs at Phathom (PHAT) - Stock Titan
3.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):